SrasV1, PubMed, Curation, bibRecord, 001508

Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.

Identifieur interne : 001508 ( PubMed/Curation ); précédent : 001507; suivant : 001509

Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.

Auteurs : Prasenjit Mukherjee [États-Unis] ; Falgun Shah ; Prashant Desai ; Mitchell Avery

Source :

Journal of chemical information and modeling [ 1549-960X ] ; 2011.

RBID : pubmed:21604711

Descripteurs français

KwdFr :
- Concentration inhibitrice 50, Conception de médicament, Conformation des protéines, Cysteine endopeptidases (), Inhibiteurs de protéases (), Inhibiteurs de protéases (pharmacologie), Interface utilisateur, Protéines virales (), Protéines virales (antagonistes et inhibiteurs), Simulation de dynamique moléculaire, Solvants (), Virus du SRAS (enzymologie), Évaluation préclinique de médicament ().
MESH :
- antagonistes et inhibiteurs : Protéines virales.
- enzymologie : Virus du SRAS.
- pharmacologie : Inhibiteurs de protéases.
- Concentration inhibitrice 50, Conception de médicament, Conformation des protéines, Cysteine endopeptidases, Inhibiteurs de protéases, Interface utilisateur, Protéines virales, Simulation de dynamique moléculaire, Solvants, Évaluation préclinique de médicament.

English descriptors

KwdEn :
- Cysteine Endopeptidases (chemistry), Drug Design, Drug Evaluation, Preclinical (methods), Inhibitory Concentration 50, Molecular Dynamics Simulation, Protease Inhibitors (chemistry), Protease Inhibitors (pharmacology), Protein Conformation, SARS Virus (enzymology), Solvents (chemistry), User-Computer Interface, Viral Proteins (antagonists & inhibitors), Viral Proteins (chemistry).
MESH :
- chemical , antagonists & inhibitors : Viral Proteins.
- chemical , chemistry : Cysteine Endopeptidases, Protease Inhibitors, Solvents, Viral Proteins.
- enzymology : SARS Virus.
- methods : Drug Evaluation, Preclinical.
- chemical , pharmacology : Protease Inhibitors.
- Drug Design, Inhibitory Concentration 50, Molecular Dynamics Simulation, Protein Conformation, User-Computer Interface.

Abstract

SARS-CoV from the coronaviridae family has been identified as the etiological agent of Severe Acute Respiratory Syndrome (SARS), a highly contagious upper respiratory disease that reached epidemic status in 2002. SARS-3CL(pro), a cysteine protease indispensible to the viral life cycle, has been identified as one of the key therapeutic targets against SARS. A combined ligand and structure-based virtual screening was carried out against the Asinex Platinum collection. Multiple low micromolar inhibitors of the enzyme were identified through this search, one of which also showed activity against SARS-CoV in a whole cell CPE assay. Furthermore, multinanosecond explicit solvent simulations were carried out using the docking poses of the identified hits to study the overall stability of the binding site interactions as well as identify important changes in the interaction profile that were not apparent from the docking study. Cumulative analysis of the evaluated compounds and the simulation studies led to the identification of certain protein-ligand interaction patterns which would be useful in further structure based design efforts.

DOI: 10.1021/ci1004916
PubMed: 21604711

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001508

Links to Exploration step

pubmed:21604711

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.</title>
<author><name sortKey="Mukherjee, Prasenjit" sort="Mukherjee, Prasenjit" uniqKey="Mukherjee P" first="Prasenjit" last="Mukherjee">Prasenjit Mukherjee</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, Mississippi 38677, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, Mississippi 38677</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shah, Falgun" sort="Shah, Falgun" uniqKey="Shah F" first="Falgun" last="Shah">Falgun Shah</name>
</author>
<author><name sortKey="Desai, Prashant" sort="Desai, Prashant" uniqKey="Desai P" first="Prashant" last="Desai">Prashant Desai</name>
</author>
<author><name sortKey="Avery, Mitchell" sort="Avery, Mitchell" uniqKey="Avery M" first="Mitchell" last="Avery">Mitchell Avery</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21604711</idno>
<idno type="pmid">21604711</idno>
<idno type="doi">10.1021/ci1004916</idno>
<idno type="wicri:Area/PubMed/Corpus">001508</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001508</idno>
<idno type="wicri:Area/PubMed/Curation">001508</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001508</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.</title>
<author><name sortKey="Mukherjee, Prasenjit" sort="Mukherjee, Prasenjit" uniqKey="Mukherjee P" first="Prasenjit" last="Mukherjee">Prasenjit Mukherjee</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, Mississippi 38677, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, Mississippi 38677</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shah, Falgun" sort="Shah, Falgun" uniqKey="Shah F" first="Falgun" last="Shah">Falgun Shah</name>
</author>
<author><name sortKey="Desai, Prashant" sort="Desai, Prashant" uniqKey="Desai P" first="Prashant" last="Desai">Prashant Desai</name>
</author>
<author><name sortKey="Avery, Mitchell" sort="Avery, Mitchell" uniqKey="Avery M" first="Mitchell" last="Avery">Mitchell Avery</name>
</author>
</analytic>
<series><title level="j">Journal of chemical information and modeling</title>
<idno type="eISSN">1549-960X</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cysteine Endopeptidases (chemistry)</term>
<term>Drug Design</term>
<term>Drug Evaluation, Preclinical (methods)</term>
<term>Inhibitory Concentration 50</term>
<term>Molecular Dynamics Simulation</term>
<term>Protease Inhibitors (chemistry)</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>Protein Conformation</term>
<term>SARS Virus (enzymology)</term>
<term>Solvents (chemistry)</term>
<term>User-Computer Interface</term>
<term>Viral Proteins (antagonists & inhibitors)</term>
<term>Viral Proteins (chemistry)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Concentration inhibitrice 50</term>
<term>Conception de médicament</term>
<term>Conformation des protéines</term>
<term>Cysteine endopeptidases ()</term>
<term>Inhibiteurs de protéases ()</term>
<term>Inhibiteurs de protéases (pharmacologie)</term>
<term>Interface utilisateur</term>
<term>Protéines virales ()</term>
<term>Protéines virales (antagonistes et inhibiteurs)</term>
<term>Simulation de dynamique moléculaire</term>
<term>Solvants ()</term>
<term>Virus du SRAS (enzymologie)</term>
<term>Évaluation préclinique de médicament ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Cysteine Endopeptidases</term>
<term>Protease Inhibitors</term>
<term>Solvents</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Evaluation, Preclinical</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de protéases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Design</term>
<term>Inhibitory Concentration 50</term>
<term>Molecular Dynamics Simulation</term>
<term>Protein Conformation</term>
<term>User-Computer Interface</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Concentration inhibitrice 50</term>
<term>Conception de médicament</term>
<term>Conformation des protéines</term>
<term>Cysteine endopeptidases</term>
<term>Inhibiteurs de protéases</term>
<term>Interface utilisateur</term>
<term>Protéines virales</term>
<term>Simulation de dynamique moléculaire</term>
<term>Solvants</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">SARS-CoV from the coronaviridae family has been identified as the etiological agent of Severe Acute Respiratory Syndrome (SARS), a highly contagious upper respiratory disease that reached epidemic status in 2002. SARS-3CL(pro), a cysteine protease indispensible to the viral life cycle, has been identified as one of the key therapeutic targets against SARS. A combined ligand and structure-based virtual screening was carried out against the Asinex Platinum collection. Multiple low micromolar inhibitors of the enzyme were identified through this search, one of which also showed activity against SARS-CoV in a whole cell CPE assay. Furthermore, multinanosecond explicit solvent simulations were carried out using the docking poses of the identified hits to study the overall stability of the binding site interactions as well as identify important changes in the interaction profile that were not apparent from the docking study. Cumulative analysis of the evaluated compounds and the simulation studies led to the identification of certain protein-ligand interaction patterns which would be useful in further structure based design efforts.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21604711</PMID>
<DateCompleted><Year>2011</Year>
<Month>10</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-960X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>51</Volume>
<Issue>6</Issue>
<PubDate><Year>2011</Year>
<Month>Jun</Month>
<Day>27</Day>
</PubDate>
</JournalIssue>
<Title>Journal of chemical information and modeling</Title>
<ISOAbbreviation>J Chem Inf Model</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.</ArticleTitle>
<Pagination><MedlinePgn>1376-92</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1021/ci1004916</ELocationID>
<Abstract><AbstractText>SARS-CoV from the coronaviridae family has been identified as the etiological agent of Severe Acute Respiratory Syndrome (SARS), a highly contagious upper respiratory disease that reached epidemic status in 2002. SARS-3CL(pro), a cysteine protease indispensible to the viral life cycle, has been identified as one of the key therapeutic targets against SARS. A combined ligand and structure-based virtual screening was carried out against the Asinex Platinum collection. Multiple low micromolar inhibitors of the enzyme were identified through this search, one of which also showed activity against SARS-CoV in a whole cell CPE assay. Furthermore, multinanosecond explicit solvent simulations were carried out using the docking poses of the identified hits to study the overall stability of the binding site interactions as well as identify important changes in the interaction profile that were not apparent from the docking study. Cumulative analysis of the evaluated compounds and the simulation studies led to the identification of certain protein-ligand interaction patterns which would be useful in further structure based design efforts.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mukherjee</LastName>
<ForeName>Prasenjit</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, Mississippi 38677, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shah</LastName>
<ForeName>Falgun</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Desai</LastName>
<ForeName>Prashant</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Avery</LastName>
<ForeName>Mitchell</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>N01 AI030048</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>N01AI30048</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>N01-AI-30048</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2011</Year>
<Month>05</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Chem Inf Model</MedlineTA>
<NlmUniqueID>101230060</NlmUniqueID>
<ISSNLinking>1549-9596</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012997">Solvents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="C099456">3C-like proteinase, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056004" MajorTopicYN="Y">Molecular Dynamics Simulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012997" MajorTopicYN="N">Solvents</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014584" MajorTopicYN="Y">User-Computer Interface</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>5</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>5</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>10</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">21604711</ArticleId>
<ArticleId IdType="doi">10.1021/ci1004916</ArticleId>
<ArticleId IdType="pmc">PMC3929308</ArticleId>
<ArticleId IdType="mid">NIHMS298995</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Med Chem. 2005 Feb 10;48(3):805-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15689164</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2005 May 5;48(9):3164-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15857122</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 Jun;79(11):7095-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15890949</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2005 Jun 30;48(13):4469-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15974598</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2005 Aug 11;48(16):5108-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16078830</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2005 Sep 2;280(35):31257-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15788388</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Nov 1;61(Pt 11):964-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16511208</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5717-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16581910</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2006 Aug 10;49(16):4971-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16884309</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2006 Aug 24;49(17):5154-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16913704</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2006 Dec 1;16(23):5993-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16971117</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Screen. 2006 Dec;11(8):915-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17092912</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Pharm Des. 2006;12(35):4555-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17168761</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2007 Feb 23;366(3):916-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17196984</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Protein Pept Sci. 2007 Feb;8(1):19-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17305557</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Disord Drug Targets. 2007 Mar;7(1):29-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17346209</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2007 May 31;50(11):2640-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17461565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochemistry. 2007 Jul 31;46(30):8744-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17605471</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2007 Aug 24;371(4):1060-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17599357</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2007 Nov 1;17(21):5876-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17855091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 2007 Dec 15;15(24):7795-802</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17888664</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2007 Nov 29;50(24):5912-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17985862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 2008 Jan 1;16(1):293-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17931870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2008 Mar;82(5):2515-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18094151</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Angew Chem Int Ed Engl. 2008;47(17):3275-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18348134</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 2008 Apr 1;16(7):4138-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18343121</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 2008 Apr 15;16(8):4652-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18329272</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1986-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Biol. 2005 Oct;3(10):e324</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16128623</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2005 Nov 11;353(5):1137-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16219322</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2005 Nov 3;48(22):6767-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16250632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2005 Nov 18;354(1):25-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16242152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Model. 2005 Nov-Dec;45(6):1759-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16309282</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2005 Dec 29;48(26):8253-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16366607</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2006 Feb 9;49(3):1198-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16451084</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Mol Med. 2003 Aug;9(8):325-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12928032</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2003 Oct 15;37(8):1139-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14523782</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14585926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 Jan 16;279(3):1637-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14561748</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochemistry. 2004 Apr 20;43(15):4568-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15078103</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochemistry. 2004 May 4;43(17):4906-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15109248</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Comput Sci. 2004 May-Jun;44(3):1177-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15154787</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2004 Jun 4;279(23):24765-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15037623</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Biol. 2004 Oct;11(10):1445-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15489171</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbiol Rev. 1993 Dec;57(4):781-822</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8302216</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 1996 Jul 19;39(15):2887-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8709122</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 1996 Aug 2;39(16):3049-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8759626</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1997 May;71(5):3992-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9094676</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 1997 Apr 11;40(8):1219-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9111296</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 2008 May 1;16(9):5254-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18362073</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Biol. 2008 Jun;15(6):597-606</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18559270</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Biol Drug Des. 2008 Jul;72(1):34-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18611220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Chem. 2008 Oct;36(5):229-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18295820</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Pharm Bull (Tokyo). 2008 Oct;56(10):1400-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18827378</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ChemMedChem. 2008 Oct;3(10):1535-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18688907</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2008 Oct 15;18(20):5684-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18796354</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Recent Pat Antiinfect Drug Discov. 2008 Nov;3(3):157-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18991798</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEBS Lett. 2009 Feb 4;583(3):549-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19166843</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Disord Drug Targets. 2009 Apr;9(2):223-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19275708</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2009 Jun 1;19(11):2965-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19410454</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Pharmacother. 2009 Jul;10(10):1615-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19527188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Model. 2009 Aug;15(8):897-911</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19172319</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Chem Biol. 2009 Jun 19;4(6):473-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19413326</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ChemMedChem. 2009 Aug;4(8):1317-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19472268</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2009 Sep 1;19(17):5186-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19632840</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Med. 2009 Dec;122(12):1150.e11-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19958895</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Graph Model. 2010 Apr;28(7):695-706</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20153225</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Comput Aided Drug Des. 2010 Mar;6(1):1-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20370692</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Chem Chemother. 2000 Jan;11(1):1-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10693650</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2000 Apr;81(Pt 4):853-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10725411</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Comput Sci. 2001 Mar-Apr;41(2):233-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11277704</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Chem Soc. 2001 Feb 7;123(5):886-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11456622</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 2002 Jan 21;12(2):221-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11755359</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2002 Sep 12;45(19):4350-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12213076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biopolymers. 2002;66(2):101-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12325160</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Rev. 2002 Dec;102(12):4609-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12475203</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Rev. 2002 Dec;102(12):4639-750</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12475205</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Graph Model. 2010 Jun;28(8):766-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20227312</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Model. 2010 May 24;50(5):906-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20392095</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>SAR QSAR Environ Res. 1998;8(1-2):23-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9517009</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Rev. 1998 Oct;11(4):614-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9767059</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem Lett. 1998 Jul 7;8(13):1697-702</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9873418</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Org Biomol Chem. 2004 Nov 21;2(22):3204-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15534697</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2004 Dec 2;47(25):6113-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15566280</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2005 Jan 7;280(1):164-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15507456</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2005 Jan 13;48(1):240-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15634017</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chem Inf Model. 2005 Jan-Feb;45(1):10-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15667124</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001508 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001508 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:21604711
   |texte=   Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:21604711" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.

Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki